Fresh off of #ASCO26, I'm compelled to share more about how NCI-funded research fuels progress. Our #YourNCI initiative describes how @theNCI—through critical funding and hands-on science across the cancer continuum—advances research, leading to better outcomes for patients.

Right before #asco26, we lost crc patient advocate @CancerInsider Here's a collection of videos, interviews, webinarspistec in the Early Onset CRC FB group @ejgallagher1 Invited to be part of @asco voices in 2024 and the white House crc summit. m.facebook.com/groups/earlyo…

For decades, NIH-funded scientists studied KRAS when pharma considered it "undruggable." KRAS-targeted therapies like daraxonrasib are the result of decades of federally funded basic science. This is exactly the wrong moment to be cutting federal research funding

The timing could not be worse. At #ASCO2026, we saw #daraxonrasib double survival in #PDAC, a reminder that decades of NIH research investment are paying off. Yet federal research funding is being cut. The biggest victims won't be scientists... They'll be future patients

Fantastic educational session happening right now @ASCO on immunotherapy in colorectal cancer. Such thoughtful and brilliant colleagues (Stacey Cohen, Chris Lieu and @KaiKeenShiu) and friends!

Historic. Daraxonrasib did not come from nowhere. It stands on decades of #NIH & #NCI supported work on RAS biology to tackle one of cancer’s most stubborn “undruggable” targets. Credit Revolution Medicines for execution and clinical development. We should also credit the public federally funded research ecosystem that made the target, tools, and translational path possible.

Twice today already at ASCO I have heard presenters say “patients failed treatment”. Can we please, please stop that? Treatments fail patients, not the other way around…

Incredibly moving moment. I think there were likely some tears (or almost tears) too! 💪🥹 #ASCOGI

The overall survival curves for Daraxonrasib in 2nd line advanced #PancreaticCancer leave no doubt how impactful this advance is for the field & for patients. Congratulations Brian Wolpin, @EileenMOReilly & @md_oberstein et al. A seminal #ASCO26 plenary! nejm.org/doi/full/10.1056/NE…

I just learned #cancer #surgical icon of the #nonoperativemanagement approach to #rectalcancer Dr. Angelita Habr-Gama just passed away today at the age of 93. She was AMAZING! She has changed our views on the necessity of surgery in the setting of cCR. #groundbreaking #cancerresearch #originaldisruptor

Our #ASCO26: #BREAKWATER #PFS and #OS results with the FOLFIRI chemo backbone in #BRAFV600E MT #colorectalcancer. 👉PFS: Median 15.2 vs. 8.3M, HR = 0.44 👉 OS: Median NR vs. 20.3M, HR = 0.53 We are so glad to provide another option for our pts! @PfizerOncMed @ASCO #cancer #cancerresearch @OncoAlert

Come check out a phase I study of a novel ADC (BC3195) targeting cadherin-3 (CDH-3) at poster 172! #ASCO26 Also - find yourself colleagues that bring you grilled cheese and caffeine during your 2nd poster session of the day! ☺️😋 #readytogo @LumishMelissa @lauren_henke

1/A few years into my career, I started a quiet game at #ASCO. I would stop at a poster, read the title, and try to work out what the team actually had going for them. Do this for the past 5 years and a pattern appears:

Cancer survival in the U.S. just crossed 70%. It was 63% in the 1990s. That gap = 4.8M people alive today. This one chart captures survival gains across 29 cancer types. The wins are real. So is the unfinished work. ▪️CML: 31% → 72% ▪️Multiple myeloma: 32% → 62% ▫️Kidney: 59% → 82% ▫️Metastatic melanoma: 16% → 35% ▫️Childhood ALL: 80% → 92% But some cancers barely moved. Cervical cancer outcomes actually worsened. None of this is abstract progress, though. These are birthdays, grandkids, and years of life returned. This is what funded science does. Next time someone asks if cancer research works, show them this (full) chart. - - - - - Source: ACS Cancer Statistics 2026 · SEER · 𝘷𝘪𝘢 @Jori_health - - - - -

The worst cancers with respect to lethality get the least federal funding support jamanetwork.com/journals/jam…

Every cancer drug you prescribe today was once an NIH grant nobody noticed. Pharma celebrates launches. Few notice the 20–40 year runway behind that. Gleevec took 41 years from NIH-funded discovery of the Philadelphia chromosome → FDA approval. Behind every “breakthrough” sits a graveyard of failed attempts that made it possible. Cut that lineage today, the next Gleevec doesn’t arrive in 2067. Funded science matters. If someone says NIH funded science is inefficient, show them this. - - - - - Source: NIH RePORTER · FDA · via @Jori_health - - - - -

Early phase daraxonrasib trial data out. Safety study (with high grade 3 AEs). For those looking for some idea of response, appears to be about 30-35%, median duration 8mo in previously treated PDAC

Feeling stupid is a crucial part of science. It means you're pushing into the unknown where real discoveries happen.

No, you should not actually have to personally experience something before you can show compassion to another human being who is currently experiencing it. You shouldn’t even have to know someone personally who’s experienced it. That’s what makes it compassion.

Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch @OncoAlert